Pasadena, Calif.-based Circularity Healthcare LLC has initiated a clinical trial to evaluate its transdermal microcirculation device in COVID-19 patients with underlying health conditions. The aim is to see if use of the noninvasive deoxyhemoglobin vasodilator (from which the product derives its name) improves outcomes in patients suffering from coronavirus-related complications.